Trial Profile
Phase Ib/IIa Study of Cabazitaxel Plus Bavituximab for Patients With Castration-resistant Prostate Cancer Previously Treated With Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bavituximab (Primary) ; Cabazitaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- 01 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 27 Nov 2012 Lead centre changed from University of California, Irvine to Medical University of South Carolina as reported by ClinicalTrials.gov.
- 27 Nov 2012 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.